UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023217
Receipt number R000026658
Scientific Title A phase II trial of conversion surgery after induction chemotherapy(Gemcitabine+nab-Paclitaxel) and chemoradiotherapy(RT+S-1) for the patients with locally advanced pancreatic cancer.
Date of disclosure of the study information 2016/09/01
Last modified on 2021/01/19 11:01:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A phase II trial of conversion surgery after induction chemotherapy(Gemcitabine+nab-Paclitaxel) and chemoradiotherapy(RT+S-1) for the patients with locally advanced pancreatic cancer.

Acronym

GENPARTS-CS trial

Scientific Title

A phase II trial of conversion surgery after induction chemotherapy(Gemcitabine+nab-Paclitaxel) and chemoradiotherapy(RT+S-1) for the patients with locally advanced pancreatic cancer.

Scientific Title:Acronym

GENPARTS-CS trial

Region

Japan


Condition

Condition

Pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine Hepato-biliary-pancreatic surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Efficacy

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

The R0 resection rate

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

Conversion surgery after Chemotherapy and Radiochemotherapy

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1) It is histologically or cytologically diagnosed as pancreatic cancer.
2) Unresectable locally advanced pancreatic cancer according to NCCN guideline 2016
3) Age from 20 to 80 years.
4) ECOG performance status of 0 or 1
5) No previous treatment
6) Labo data to entry satisfy following criteria
1. White blood cell >=3,500/mm3, <12,000/mm3
2. Neutro >=2000/mm3
3. Hb >=9.0/dl
4. T-Bil<=2.0mg/dl (<=3.0mg/dl, after biliary drainage)
5. AST and ALT<=150IU/l
6. serum creatinine<=1.2mg/dl
7. eGFR>=60ml/min
7) Written informed consent

Key exclusion criteria

1) -1 Initially diagnosed as resectable pancreatic cancer
-2 Initially diagnosed as unresectable pancreatic cancer with distant metastasis
2) Age: over 80 years, or less than 20 years
3) ECOG performance status =>2
4) Previous treatments
5) Labodata do not satisfy inclusion criteria
6) No written informed consent
7) Inadequate physical condition, as diagnosed by primary physician

Target sample size

75


Research contact person

Name of lead principal investigator

1st name Minoru
Middle name
Last name Tanabe

Organization

Tokyo Medical and Dental University

Division name

Hepatobiliary and Pancreatic Surgery

Zip code

113-8519

Address

Bunkyo-ku, Yushima 1-5-45, Tokyo, Japan

TEL

03-5803-5928

Email

tana.msrg@tmd.ac.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name Ban

Organization

Tokyo Medical and Dental University

Division name

Hepatobiliary and Pancreatic Surgery

Zip code

113-8519

Address

Bunkyo-ku, Yushima 1-5-45 TMDU HepatoBiliaryPanc Surg

TEL

03-5803-5928

Homepage URL


Email

d-ban.msrg@tmd.ac.jp


Sponsor or person

Institute

Ochanomizu Gastrointestinal Oncology Group

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research ethics committee, Tokyo Medical and Dental University

Address

Bunkyo-ku, Yushima 1-5-45, Tokyo, Japan

Tel

03-5803-5096

Email

syomu1.adm@tmd.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 09 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

11

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2016 Year 08 Month 15 Day

Date of IRB

2016 Year 08 Month 19 Day

Anticipated trial start date

2016 Year 09 Month 01 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 07 Month 18 Day

Last modified on

2021 Year 01 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026658


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name